Regorafenib inhibits EphA2 phosphorylation and leads to liver damage via the ERK/MDM2/p53 axis

The hepatotoxicity of regorafenib is one of the most noteworthy concerns for patients, however the mechanism is poorly understood. Hence, there is a lack of effective intervention strategies. Here, by comparing the target with sorafenib, we show that regorafenib-induced liver injury is mainly due to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Hao, Wu, Wentong, Hu, Yuhuai, Li, Jinjin, Xu, Jiangxin, Chen, Xueqin, Xu, Zhifei, Yang, Xiaochun, Yang, Bo, He, Qiaojun, Luo, Peihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182995/
https://www.ncbi.nlm.nih.gov/pubmed/37179400
http://dx.doi.org/10.1038/s41467-023-38430-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182995/
https://www.ncbi.nlm.nih.gov/pubmed/37179400
http://dx.doi.org/10.1038/s41467-023-38430-8

Ejemplares similares